ArticlePloS one2026
Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsSteatotic liver disease (SLD) has emerged as an important risk factor for hepatocellular carcinoma (HCC), often in the absence of cirrhosis. We aimed to develop explainable machine learning (ML) models to predict HCC risk in individuals with SLD using routinely collected screening data.
methodsUsing the Korean National Health Insurance Service database, we included adults aged 20-79 years who underwent national health screening in 2017. SLD was defined as a fatty liver index (FLI) ≥ 60. Multiple ML algorithms, including deep learning models, were trained using a 7:3 train-test split with repeated non-replacement undersampling at a 1:3 case-to-control ratio to address extreme class imbalance.
resultsAmong 1,241,560 adults with SLD, 2,152 (0.17%) developed HCC during a 6-year follow-up period. In the internal validation cohort, the final weighted multi-head attention deep neural network ensemble achieved an area under the receiver operating characteristic curve of 0.923, with a sensitivity of 71.36% and specificity of 93.65%. SHapley Additive exPlanations consistently identified age, sex, triglycerides, total cholesterol, aminotransferases, gamma-glutamyl transferase (GGT), Charlson Comorbidity Index, and FLI as key contributors to HCC risk. In multivariable Cox models, older age, male sex, elevated GGT, higher aspartate aminotransferase and FLI, and greater comorbidity burden were positively associated with HCC risk, whereas higher triglyceride and total cholesterol levels were inversely associated. Model-based risk stratification identified four groups with distinct HCC-free survival curves; the extremely high-risk group had an approximately 74.9-fold higher hazard of HCC than the low-risk group (95% CI, 55.3-101.5).
conclusionsOverall, this explainable ML model based on routine health screening variables enables robust HCC risk stratification and may help inform future targeted surveillance strategies in SLD populations after external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.